Viomi Technology Co., Ltd to Report First Quarter 2022 Financial Results on Friday, May 27, 2022
Viomi Technology Co., Ltd to Report First Quarter 2022 Financial Results on Friday, May 27, 2022 |
| [16-May-2022] |
Earnings Call Scheduled for 8:00 a.m. ET on May 27, 2022 GUANGZHOU, China, May 16, 2022 /PRNewswire/ -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ: VIOT), a leading IoT @ Home technology company in China, today announced that it will report its first quarter 2022 unaudited financial results on Friday, May 27, 2022, before the open of the U.S. markets. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 27, 2022 (8:00 PM Beijing/Hong Kong time on May 27, 2022). Dial-in details for the earnings conference call are as follows:
Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at http://ir.viomi.com. A replay of the conference call will be accessible by phone one hour after the conclusion of the live call at the following numbers, until June 3, 2022:
About Viomi Technology Viomi's mission is to redefine the future home via the concept of IoT @ Home. Viomi has developed a unique IoT @ Home platform consisting an ecosystem of innovative IoT-enabled smart home products, together with a suite of complementary consumable products and value-added businesses. This platform provides an attractive entry point into the consumer home, enabling consumers to intelligently interact with a broad portfolio of IoT products in an intuitive and human-like manner to make daily life more convenient, efficient and enjoyable, while allowing Viomi to grow its household user base and capture various additional scenario-driven consumption events in the home environment. For more information, please visit: http://ir.viomi.com. For investor and media inquiries, please contact: In China: Viomi Technology Co., Ltd The Piacente Group, Inc. In the United States: The Piacente Group, Inc.
SOURCE Viomi Technology Co., Ltd | |||||||||||||||||||||||
Company Codes: NASDAQ-NMS:VIOT |
View original content:© 2022 PR Newswire. All Rights Reserved.
NRx Pharmaceuticals (Nasdaq: NRXP): FDA Declines Emergency Use Authorization for ZYESAMI (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir
